Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Ovarian Cancer: Update Bulletin #3 [January 2019]

Product Code:
596201006
Publication Date:
January 2019
Format:
PDF
Price:
$1,315

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the ovarian cancer market. KOLs provide their candid insights on key events, including: the Phase III SOLO-3 trial of Lynparza (olaparib; AstraZeneca/Merck & Co.) meeting its primary endpoint of significantly improving objective response rate (ORR), compared with chemotherapy, in platinum-sensitive patients with relapsed BRCA-mutated ovarian cancer who have had two or more prior lines of chemotherapy; the presentation of preliminary data from the FORWARD II trial expansion cohort of the antibody-drug conjugate mirvetuximab soravtansine (ImmunoGen) in combination with pembrolizumab (Keytruda; Merck & Co.); the discontinuation of the Phase III JAVELIN Ovarian 100 trial of avelumab (Bavencio; Merck Group/Pfizer) after a planned interim analysis showed it would not meet its primary endpoint of PFS.

Business Questions:

• How do KOLs view the positive outcome from the SOLO-3 trial of Lynparza?
• Could the approval of Lynparza as a first-line maintenance therapy, on the basis of the SOLO-1 study, lessen the impact of the SOLO-3 data?
• How do KOLs interpret the positive data released from the FORWARD II trial expansion cohort of ImmunoGen’santibody drug conjugate mirvetuximab in combination with Merck & Co.’s pembrolizumab (Keytruda)?
• Could folate receptor alpha be a valid target for therapeutic intervention in ovarian cancer?
• How is the potential safety and tolerability profile of mirvetuximab plus pembrolizumab viewed?
• What are KOL reactions to the failure of the Phase III JAVELIN Ovarian 100 trial of Merck Group/Pfizer’s avelumab (Bavencio)?
• Considering the failure of the Phase III JAVELIN Ovarian 100 and 200 trials, how do KOLs now view the prospects for PD-1/L1 inhibitors to find success in ovarian cancer?




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved